Trials / Completed
CompletedNCT02535286
Study of Immunotherapy in Combination With Ublituximab and Umbralisib in Patients With Relapsed-refractory CLL or Richter's Transformation
Phase I Study of Ublituximab and Umbralisib in Combination With Targeted Immunotherapy in Patients With Relapsed-refractory Chronic Lymphocytic Leukemia (CLL) or Richter's Transformation (RT) of CLL
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 27 (actual)
- Sponsor
- TG Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and effectiveness of targeted immunotherapy in combination with ublituximab and umbralisib, in patients with advanced CLL or Richter's Transformation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Umbralisib | A once daily oral agent |
| BIOLOGICAL | ublituximab | IV anti-CD20 monoclonal antibody |
| BIOLOGICAL | TG-1501 | IV immunotherapy for cancer |
Timeline
- Start date
- 2015-09-18
- Primary completion
- 2021-11-04
- Completion
- 2021-11-04
- First posted
- 2015-08-28
- Last updated
- 2022-10-20
Locations
4 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02535286. Inclusion in this directory is not an endorsement.